Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. - Wikidata - wikimedia - TriplyDB

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

http://www.wikidata.org/entity/Q30440705

about

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Corneal neovascularization and biological therapy A review of anti-VEGF agents for proliferative diabetic retinopathy Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report.Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus Corneal neovascularization: an anti-VEGF therapy review.Real-Time PCR-Coupled CE-SELEX for DNA Aptamer Selection Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema.Emerging roles for antiangiogenesis factors in management of ocular disease.Drug-induced uveitis Aflibercept in wet AMD: specific role and optimal use.Development of crystalline keratopathy after intravitreal injections of pegaptanib.Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.Neovascular age-related macular degeneration.Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters.Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review.Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.Emerging treatments for wet age-related macular degeneration.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Antivascular endothelial growth factor agents for neovascular age-related macular degeneration.Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports.Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.Anti-vascular endothelial growth factor in age-related macular degeneration: puzzle or a silent beginning!Therapeutic Modalities of Exudative Age-related Macular Degeneration.Compassionate use of intravitreal pegaptanib in patients with age-related macular degeneration.Effects of pegaptanib sodium on retinal function in isolated perfused vertebrate retina.Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study).A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration.Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.

P2860

Q24194251-136D9771-A515-4B14-BF91-94F6F632528D Q26771522-A460624C-E01A-42A2-8D77-863EDDAA798A Q26776229-9B76BEAC-8636-4A2C-B481-6D46D44122A4 Q27025643-9B1699C5-2063-4B82-922F-CD50C0575582 Q30979491-663BC783-97A0-4AE4-92B3-9404C559CFD8 Q31061150-835C89A8-CF8E-4D8A-A3AF-744D7B5F4B6B Q33760560-B623EF22-58CD-49BF-91CA-A36AFF26D8B4 Q34346463-70118F56-CF72-4306-BADF-93E3AB232B04 Q34370043-040E265A-2276-42AF-A3B9-9C2A3D6BABE7 Q34641522-0423A04E-1DFA-409E-8AF2-579E0DC644AA Q36059615-8681CA74-A121-4891-9BB5-0ACD957E79E9 Q36391018-74E8A7D5-CAF7-4D92-9E52-F7A8AEBB6423 Q36696513-22863AAD-44A9-403B-A87E-5D42D43A490A Q36797491-189158A2-C876-462E-8E49-4EDB9F4FAB6D Q37109788-81630EE2-A537-4000-9BEF-DC2782EED7A5 Q37649707-44629D9B-9B05-45B4-86B4-ACD5812A5AD0 Q37973348-05634B51-1B79-4E7F-BDB6-D1C9BA4BC718 Q38003861-4A835BB6-F1F5-4FCB-9DF9-EF78F4D485F9 Q38104396-470E0261-662C-489B-ADB1-76E86FF25CF9 Q38130492-7BFE51FF-C359-4E44-8D75-91380D017606 Q38168825-8FC44F19-0E01-46D5-A9A6-7C196EF1A120 Q38189808-8B69D07E-F830-4884-AB85-D5ABCC29C00D Q38210239-EB6ED80D-3EB6-4BCC-BDE9-B56D99F22A84 Q38261105-4D43B105-A27E-4EE2-B8D6-10F8B4343FB6 Q39519501-32603439-FEAC-461A-B238-293410A27475 Q39665129-9D9AD1EF-F67A-4D4C-97B8-8FC786259D00 Q41044420-05FF0747-91C6-49AE-971C-6785456DEBA7 Q41091625-E19990C9-88F3-4BA8-B16C-887DDF645CE2 Q42242450-91864ABF-A657-4F3B-B110-DD2BA5A98469 Q42276004-B937D3E2-5464-45C8-86D5-F8DBA731069D Q42426609-2BDF3D3D-C5B4-4C2E-ADB2-48C380BFDEE4 Q42881794-A4280E09-B534-48FF-9531-2B52123E9F71 Q43021628-68A88C23-9BA0-4E8E-AC71-90C4AC749E21 Q43052782-77582183-10A0-490E-9DED-94B2823F62F3 Q43107305-71A47C67-8023-457F-9048-F41A3740C45D Q47405816-9C3A72A6-6D55-45A3-AF09-9838687033F8 Q47995257-34C39A3C-0DF5-4890-9D90-CE69C581A303 Q48300652-6EB2C1F6-A041-4579-9B34-15FBF3A77E0F Q53373714-C8BE7A41-4ED8-4F57-851B-73E373DAF808

P2860

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

http://www.wikidata.org/entity/Q30440705

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Pegaptanib sodium for neovascu ...... ascularisation (VISION) trial.

@ast

Pegaptanib sodium for neovascu ...... ascularisation (VISION) trial.

@en

type

label

Pegaptanib sodium for neovascu ...... ascularisation (VISION) trial.

@ast

Pegaptanib sodium for neovascu ...... ascularisation (VISION) trial.

@en

prefLabel

Pegaptanib sodium for neovascu ...... ascularisation (VISION) trial.

@ast

Pegaptanib sodium for neovascu ...... ascularisation (VISION) trial.

@en

P1433

Q30440705-C6511495-BE52-4491-B4CE-4F0CDD16B008

P1476

Q30440705-4364B8CC-C8AA-475F-BD48-93B84BD62194

P2093

Q30440705-084D7451-3845-4EED-9140-1ABBBA16237C

Q30440705-17D94CF0-B4C3-42BD-ADA5-B7E967B7A72A

Q30440705-29A7CB97-5301-4480-A6CD-A8F1F925A5CD

Q30440705-6A815638-D10E-45E8-A253-0EF5F0B5DEF3

Q30440705-718D6134-CE97-472A-BEFC-BCD1D1E6150E

Q30440705-8971467E-4C2F-470F-95E6-43BEF43E96E3

Q30440705-BD347DFF-D145-47D8-8E5D-22A0B35EF8EB

Q30440705-CAFB55D3-8077-4696-8A29-9739A8FF3922

Q30440705-F46FFE37-66BE-43BE-840C-05D72AD431EC

P2860

Q30440705-04083BA0-597F-43CD-AA86-84BB37B52EFD

Q30440705-05C3DE3F-E846-4FA5-8ABA-F327F751288C

Q30440705-0B92F50F-4CA6-4D70-980E-11996D8AFA4A

Q30440705-0CE7D3DD-E881-4CD0-A9CA-6292598DE0B4

Q30440705-0F91EF47-CB46-4140-996A-A7E431ED99B2

Q30440705-10627A0B-821F-4B73-802A-DF830D5A5E7B

Q30440705-11E65F33-2A5F-4545-A8E7-D9139D48226A

Q30440705-1C077D14-F17C-4048-97BB-A6AF7F8BB3B6

Q30440705-1D258687-AD24-477A-961A-0FF30F1A83A9

Q30440705-3F272051-53B2-44EC-827D-FBA9C8199C1C

P304

Q30440705-03CA4E1E-49D3-4A31-AB21-3ECF8782ECE9

P31

Q30440705-E15CC1D6-EEF4-4326-A41D-4B2D3FB5EC7A

P356

Q30440705-63807B1E-EEEC-4F23-8E14-B333E70EA8A5

P407

Q30440705-08AED69D-E33B-4B62-92FF-2417261706CB

P433

Q30440705-550C43CD-AD5B-43B7-A1D5-C3E4D711E3A7

P478

Q30440705-ED5B6D65-B5E4-4C03-AEF6-A000F2C89785

P577

Q30440705-80BD5BC6-D6CF-4294-A9E0-DE87AE68F0B9

P5875

Q30440705-16A9224A-1F5C-414A-B1B0-47D435189E40

P698

Q30440705-D71B2E1D-E201-4CD7-8A89-E53FDDCC005C

P921

Q30440705-0EE36A00-7E78-4192-BB19-0CA99AD99BDD

P932

Q30440705-AD609B0C-D0DF-4156-9140-03FAF40FC7C5

P356

BJO.2007.132597

P1433

British Journal of Ophthalmology

P1476

Pegaptanib sodium for neovascu ...... ascularisation (VISION) trial.

@en

P2093

A P Adamis

http://www.w3.org/2001/XMLSchema#string

B Katz

http://www.w3.org/2001/XMLSchema#string

D Guyer

http://www.w3.org/2001/XMLSchema#string

E Cunningham

http://www.w3.org/2001/XMLSchema#string

H Masonson

http://www.w3.org/2001/XMLSchema#string

L J Singerman

http://www.w3.org/2001/XMLSchema#string

M Goldbaum

http://www.w3.org/2001/XMLSchema#string

M Patel

http://www.w3.org/2001/XMLSchema#string

R Buggage

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection

In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing.

Inhibitors of ocular neovascularization: promises and potential problems.

Managing patients treated with bevacizumab combination therapy.

P304

1606-1611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJO.2007.132597

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5237304

http://www.w3.org/2001/XMLSchema#string

P698

18614570

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

2584239

http://www.w3.org/2001/XMLSchema#string